secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2022-09-07T23:59:59+00:00
Accession:  0001104659-22-098035
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics DKN-01 combo shows 11.3-month median PFS and 68% ORR in first-line gastric cancer at ESMO
--------------------------------------------------------------------------------

- Median PFS 11.3 months in overall first-line GEA patients in DisTinGuish study, exceeding benchmarks.
- ORR 68% overall, 90% in DKK1-high, 79% in PD-L1-low subgroups.
- Median OS not mature; 44% deceased as of June 30, 2022 cut; enrollment ongoing for randomized Part C.
- WAKING study (DKN-01 + atezolizumab) in 2nd/3rd-line OGA: 18 enrolled, DCR 50%, 1 PR; safety tolerable.
- Appointed Richard Schilsky, MD (former ASCO CMO) to Board effective Sept 1, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465922098035/0001104659-22-098035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465922098035/tm2225135d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-098035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer